A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: smallest amount (9)

Audit and Risk Committee ToR Jan 2023

Description
Audit and Risk Committee Terms of Reference Version: 5 Date Issued: Review Date: Document Type: 31 Jan
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Audit-and-Risk-Committee-ToR-Jan-2023.pdf

Endometrial-Dostarlimab

Description
Chemotherapy Protocol GYNACOLOGICAL CANCER Dostarlimab Regimen  Endometrial - Dostarlimab Indication  Dostarlimab is indicated for pat
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Dostarlimab.pdf

Avelumab(800mg)

Description
Chemotherapy Protocol BLADDER CANCER AVELUMAB (800mg) Regimen  Bladder Cancer - Avelumab Indication  Avelumab is indicated as monotherap
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Avelumab800mg.pdf

Nivolumab 240mg (NSCLC)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Nivolumab (240mg-14 days) Regimen • NSCLC – Nivolumab (240mg-14days
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Nivolumab-240mg.pdf

Pazopanib v1.1

Description
Chemotherapy Protocol RENAL CELL PAZOPANIB Regimen Renal Cell - Pazopanib Indication First line treatment
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Pazopanib-v1.1.pdf

Audit and Risk Committee ToR Jan 2022

Description
Audit and Risk Committee Terms of Reference Date Issued: 27 January 2022 Review Date: January 2023 Doc
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Audit-and-Risk-Committee-ToR-Jan-2022.pdf

Appendix B - VZIG risk assessment and prescription form

Description
Varicella zoster Immunoglobulin for post-exposure prophylaxis (PEP)Please note that UHS Pharmacy will issue VZIG only when both RISK ASSESSME
Url
/Media/UHS-website-2019/Docs/Post-Exposure-Prophylaxis-Policy/AppendixB-VZIGRiskAssessmentandPrescriptionForm.pdf

Carboplatin Paclitaxel EC Pembrolizumab Neoadjuvant Ver1.0

Description
Chemotherapy Protocol BREAST CANCER PEMBROLIZUMAB WITH CARBOPLATIN/PACLITAXEL AND EC NEOADJUVANT BREAST CANCER FOLLOWED BY ADJUVANT PEMBROLIZUM
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Carboplatin-Paclitaxel-EC-Pembrolizumab-Neoadjuvant.pdf

IPD-Dexamethasone-Isatuximab-Pomalidomide

Description
Chemotherapy Protocol Myeloma Isatuximab-Dexamethasone (40)-Pomalidomide Regimen • Myeloma – Isatuximab-Dexame
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/IPD-Dexamethasone-Isatuximab-Pomalidomide.pdf

VR-RituximabVenetoclaxCycle_1_VenetoclaxDoseTitration

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia VR-RITUXIMAB-VENETOCLAX (high risk) Cycle 1 – Venetoclax dose titration Regimen •
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VR-RituximabVenetoclaxCycle-1-VenetoclaxDoseTitration.pdf
71 to 80 of 701
Previous … 6 7 8 9 10 … Next